Published in JOP on March 10, 2012
Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol (2013) 1.34
Standard imaging techniques for assessment of portal venous system and its tributaries by linear endoscopic ultrasound: a pictorial essay. Endosc Ultrasound (2013) 1.06
Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer. World J Surg (2014) 0.78
Validation of group B borderline resectable pancreatic cancer: retrospective analysis. Gut Liver (2014) 0.75
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39
Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57
Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43
Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
Thyroidectomy using local anesthesia: a report of 1,025 cases over 16 years. J Am Coll Surg (2005) 1.32
Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg (2010) 1.32
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30
Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol (2013) 1.28
Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17
Thyroidectomy using monitored local or conventional general anesthesia: an analysis of outpatient surgery, outcome and cost in 1,194 consecutive cases. World J Surg (2006) 1.17
Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07
Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06
Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04
Quantitative ultrasonic evaluation of radiation-induced late tissue toxicity: pilot study of breast cancer radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.03
Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02
Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02
Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol (2007) 1.02
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02
Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02
Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99
Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98
Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96
IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96
Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96
Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93
FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91
Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89
Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89
Neurocognitive Deficits After Radiation Therapy for Brain Malignancies. Am J Clin Oncol (2015) 0.89
Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87
Early detection of pancreatic cancer. JOP (2012) 0.87
Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87
Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87
Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87
Quality of life in patients with pancreatic cancer. JOP (2012) 0.86
Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86
Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85
Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85
Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85
Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85
Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85
Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84
Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84
Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84
Advancements in the management of pancreatic cancer. JOP (2009) 0.83
Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83
Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83
Diabetes and pancreatic cancer. JOP (2014) 0.83
PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83
First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83
Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83
Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82
The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82
Biomarkers in neuroendocrine tumors. JOP (2013) 0.82
Role of anticoagulation in the management of pancreatic cancer. JOP (2009) 0.82
Negative preoperative localization leads to greater resource use in the era of minimally invasive parathyroidectomy. Am J Surg (2009) 0.82
Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP (2009) 0.82
Locally advanced pancreatic adenocarcinoma: update and progress. JOP (2012) 0.82
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol (2012) 0.82
Elderly patients with pancreatic cancer. JOP (2014) 0.81
Novel treatment approaches for locally advanced pancreatic cancer. JOP (2014) 0.81
Metastatic pancreatic cancer: the dilemma of quality vs. quantity of life. JOP (2013) 0.81
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. JOP (2014) 0.81
Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer (2009) 0.81
Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). JOP (2015) 0.81
KRAS in pancreatic cancer. JOP (2014) 0.81